Compare PTLE & ICCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | PTLE | ICCM |
|---|---|---|
| Founded | 2013 | 2006 |
| Country | Singapore | Israel |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | |
| Sector | Energy | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.3M | 41.4M |
| IPO Year | N/A | 2013 |
| Metric | PTLE | ICCM |
|---|---|---|
| Price | $5.67 | $0.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.50 |
| AVG Volume (30 Days) | ★ 722.0K | 283.7K |
| Earning Date | 05-15-2026 | 03-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $53.39 |
| Revenue Next Year | N/A | $174.28 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.09 | $0.54 |
| 52 Week High | $16.17 | $1.40 |
| Indicator | PTLE | ICCM |
|---|---|---|
| Relative Strength Index (RSI) | 50.89 | 45.40 |
| Support Level | $0.14 | $0.58 |
| Resistance Level | $16.17 | $0.74 |
| Average True Range (ATR) | 1.80 | 0.06 |
| MACD | -0.43 | -0.01 |
| Stochastic Oscillator | 14.50 | 13.39 |
PTL Ltd is a holding company. Through its subsidiaries, it is an established bunkering facilitator providing marine fuel logistics services for vessel refuelling, serving the Asia Pacific market. The company's services mainly involve facilitating with its suppliers to supply fuel for the use by the customers' vessels at various ports along their voyages in the Asia Pacific region; arranging vessel refuelling activities at competitive pricing to the customers; offering trade credit to the customers for vessel refuelling; handling unforeseeable circumstances faced by the customers and providing contingency solutions to the customers on time; and handling disputes, mainly concerning quality and quantity issues on marine fuel. The company derives its maximum revenue from Hong Kong.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.